Project PriMo: Sharing principles and practices of bronchodilator therapy monitoring in COPD. A consensus initiative for optimizing therapeutic appropriateness among Italian specialists

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 218-228

  Cazzola, Mario ^a   Brusasco, Vito ^b   Centanni, Stefano ^c   Cerveri, Isa ^d   De Michele, Fausto ^e   Di Maria, Giuseppe ^f   Palange, Paolo ^g   Pellegrino, Riccardo ^h   Polverino, Mario ⁱ   Rossi, Andrea ^j   Papi, Alberto ^k  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h S CROCE E CARLE HOSPITAL   (Italy)

ⁱ ASL Salerno   (Italy)

^j DAI Cardiovascolare Toracico   (Italy)

^k UNIVERSITY OF FERRARA   (Italy)

more..

Author keywords

Bronchodilators; COPD; Delphi process

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID;

ADD ON THERAPY; AIRWAY OBSTRUCTION; ARTERIAL GAS; ARTICLE; BRONCHODILATATION; BRONCHUS OBSTRUCTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONSENSUS; CORTICOSTEROID THERAPY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DYSPNEA; EARLY INTERVENTION; EXERCISE TOLERANCE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL DISEASE; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; ITALY; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG VOLUME; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESIDUAL VOLUME; SPIROMETRY; SPUTUM; TOTAL LUNG CAPACITY; TREATMENT RESPONSE;

BRONCHODILATOR AGENTS; DELPHI TECHNIQUE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; ITALY; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SPECIALIZATION;

EID: 84874571203     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.10.010     Document Type: Article

References (37)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Revised 2011. http://www.goldcopd.com.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2010. http://www.goldcopd.com.
3. Qaseem A., Wilt T.J., Weinberger S.E., Hanania N.A., Criner G., van der Molen T., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
4. Murphy M., Sanderson C., Black N. Consensus development methods and their use in clinical guideline development. Health Technol Assess 1998, 2:1-100.
5. Fink A., Kosecoff J., Chassin M., Brook R.H. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984, 74:979-983.
6. Wyrwich K.W., Fihn S.D., Tierney W.M., Kroenke K., Babu A.N., Wolinsky F.D. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003, 18:196-202.
7. Flume P.A., Mogayzel P.J., Robinson K.A., Rosenblatt R.L., Quittell L., Marshall B.C. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010, 182:298-306.
8. Mahler D.A., Selecky P.A., Harrod C.G., Benditt J.O., Carrieri-Kohlman V., Curtis J.R., et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010, 137:674-691.
9. Schutt A.C., Bullington W.M., Judson M.A. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010, 104:717-723.
10. Upton J., McCutcheon E., Loveridge C., Wiggins J., Walker S., Fletcher M. What provokes experienced COPD clinical practitioners in the UK to initiate or change medication? A consensus study. Prim Care Respir J 2011, 20:155-160.
11. Ryu J.H., Scanlon P.D. Obstructive lung diseases: COPD, asthma, and many imitators. Mayo Clin Proc 2001, 76:1144-1153.
12. van den Boom G., Rutten-van Mölken M.P., Tirimanna P.R., van Schayck C.P., Folgering H., van Weel C. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J 1998, 11:67-72.
13. d'Andiran G., Schindler C., Leuenberger P. The absence of dyspnoea, cough and wheezing: a reason for undiagnosed airflow obstruction?. Swiss Med Wkly 2006, 136:425-433.
14. Shin C., Lee S., Abbott R.D., Kim J.H., Lee S.Y., In K.H., et al. Respiratory symptoms and undiagnosed airflow obstruction in middle-aged adults: the Korean health and genome study. Chest 2004, 126:1234-1240.
15. Lu M., Yao W.Z., Zhong N.S., Zhou Y.M., Wang C., Chen P., et al. Asymptomatic patients of chronic obstructive pulmonary disease in China. Chin Med J 2010, 123:1494-1499.
16. Brand P.L., Rijcken B., Schouten J.P., Koëter G.H., Weiss S.T., Postma D.S. Perception of airway obstruction in a random population sample. Relationship to airway hyperresponsiveness in the absence of respiratory symptoms. Am Rev Respir Dis 1992, 146:396-401.
17. Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60(11):925-931.
18. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57(10):847-852.
19. Cazzola M., Santus P., Castagna F., Di Marco F., Terzano C., Matera M.G., et al. Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. Respir Med 2002, 96:439-443.
20. Mak G., Hanania N.A. New bronchodilators. Curr Opin Pharmacol 2012, 12:238-245.
21. Cazzola M., Tashkin D.P. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. Chronic Obstr Pulm Dis 2009, 6:404-415.
22. 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267.
23. Jones P.W., Anderson J.A., Calverley P.M.A., Celli B.R., Ferguson G.T., Jenkins C., et al. Spencer MD and for the TORCH investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res 2011, 12:71.
24. Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:144-149.
25. Ferguson G.T. Maintenance pharmacotherapy of mild and moderate COPD: what is the evidence?. Respir Med 2011, 105:1268-1274.
26. Corrado A., Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012, 106:989-997.
27. Rodrigo G.J., Plaza V., Castro-Rodríguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012, 25:40-47.
28. Abramson M.J., Schattner R.L., Sulaiman N.D., Birch K.E., Simpson P.P., Del Colle E.A., et al. Do spirometry and regular follow-up improve health outcomes in general practice patients with asthma or COPD? A cluster randomised controlled trial. Med J Aust 2010, 193:104-109.
29. Sin D.D., Bell N.R., Svenson L.W., Man S.F. The impact of follow-up physician visits on emergency readmissions for patients with asthma and chronic obstructive pulmonary disease: a population-based study. Am J Med 2002, 112:120-125.
30. Cazzola M., Novelli G. Biomarkers in COPD. Pulm Pharmacol Ther 2010, 23:493-500.
31. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
32. Agh T., Inotai A., Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011, 82:328-334.
33. O'Donnell D.E. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:180-184.
34. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
35. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
36. Wang J., Nie B., Xiong W., Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012, 37:204-211.
37. Hasson F., Keeney S., McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000, 32:1008-1015.